Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis

References

• Center for Disease Control and PreventionDiabetes data and trends: national surveillance data – number (in millions) of civilian, non-institutionalized adults with diagnosed diabetes, United States, 1980–2009c2011 [updated March 30, 2011]. Available from: http://www.cdc.gov/diabetes/statistics/prev/national/figadults.htmAccessed November 13, 2011
   Google Scholar
• Center for Disease Control and PreventionDiabetes data and trends: national surveillance data – diabetes complicationsc2011 [updated June 16, 2011]. Available from: http://www.cdc.gov/diabetes/statistics/complications_national.htmAccessed November 13, 2011
   Google Scholar
• Centers for Disease Control and PreventionNational diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011c2011 [Updated November 8, 2011]. Available from: http://www.cdc.gov/diabetes/pubs/factsheet11.htmAccessed November 13, 2011
   Google Scholar
• NathanDMBuseJBDavidsonMBMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care20093219320318945920
   PubMed Web of Science ®Google Scholar
• RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic controlEndocr Pract20091554055919858063
   PubMed Web of Science ®Google Scholar
• KoroCEBowlinSJBourgeoisNFedderDOGlycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary reportDiabetes Care200427172014693960
   PubMed Web of Science ®Google Scholar
• BuseJBGinsbergHNBakrisGLPrimary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes AssociationCirculation200711511412617192512
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2011Diabetes Care201134Suppl 1S11S6121193625
   PubMed Web of Science ®Google Scholar
• EngJKleinmanWASinghLSinghGRaufmanJPIsolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venomJ Biol Chem1992267740274051313797
   PubMed Web of Science ®Google Scholar
• BYETTA^® (exenatide) injection. Full prescribing informationc2010 [Revised September 2010; Amylin Pharmaceuticals Inc, San Diego, CA] Available from: http://pi.lilly.com/us/byetta-pi.pdfAccessed August 20, 2011
   Google Scholar
• KimWEganJMThe role of incretins in glucose homeostasis and diabetes treatmentPharmacol Rev20086047051219074620
   PubMed Web of Science ®Google Scholar
• DiamantMVan GaalLStranksSOnce weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trialLancet20103752234224320609969
   PubMed Web of Science ®Google Scholar
• BlevinsTPullmanJMalloyJDURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetesJ Clin Endocrinol Metab2011961301131021307137
   PubMed Web of Science ®Google Scholar
• TaylorKGurneyKHanJPencekRWalshBTrautmannMExenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 yearsBMC Endocr Disord201111921529363
   PubMed Web of Science ®Google Scholar
• WyshamCBergenstalRMalloyJDURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatideDiabet Med20112870571421434995
   PubMed Web of Science ®Google Scholar
• EddyDSchlessingerLValidation of the Archimedes diabetes modelDiabetes Care2003263102311014578246
   PubMed Web of Science ®Google Scholar
• EddyDMSchlessingerLKahnRClinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetesAnn Intern Med200514325126416103469
   PubMed Web of Science ®Google Scholar
• AlperinPSoto-CamposGPeskinBUnderstanding the effect of glycemic control on macrovascular outcomes in patients with diabetes using the Archimedes Model [abstract]Diabetes201059 Abstract 879-P
   Web of Science ®Google Scholar
• KahnRAlperinPEddyDAge at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysisLancet20103751365137420356621
   PubMed Web of Science ®Google Scholar
• BrownJBNicholsGAGlauberHSBakstATen-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitusClin Ther1999211045105710440626
   PubMed Web of Science ®Google Scholar
• CramerJAPughMJThe influence of insulin use on glycemic controlDiabetes Care200528788315616237
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionNational Health and Nutrition Examination Survey (NHANES)c2011 Available from: http://www.cdc.gov/nchs/nhanes.htmAccessed June 23, 2011
   Google Scholar
• GoldMRSiegelJERussellLBWeinsteinMCCost- Effectiveness in Health and MedicineNew York, NYOxford University Press1996
   Google Scholar
• SullivanPWGhushchyanVPreference-based EQ-5D index scores for chronic conditions in the United StatesMed Decis Making20062641042016855129
   PubMed Web of Science ®Google Scholar
• AltmanDGAndersenPKCalculating the number needed to treat for trials where the outcome is time to an eventBMJ19993191492149510582940
   PubMed Web of Science ®Google Scholar
• ClevelandWSGrosseEShyuMJLocal regression modelsChambersJMHastieTStatistical Models in SNew York, NYChapman and Hall1992309376
   Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med20083591577158918784090
   PubMed Web of Science ®Google Scholar
• SkylerJSBergenstalRBonowROfor American Diabetes Association, American College of Cardiology Foundation, and American Heart AssociationIntensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart AssociationDiabetes Care20093218719219092168
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupTight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ19983177037139732337
   PubMed Web of Science ®Google Scholar